Advisors Asset Management’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$59.9K Sell
5,972
-1,278
-18% -$11.8K ﹤0.01% 1314
2026
Q2
$60.7K Buy
7,250
+123
+2% +$1.12K ﹤0.01% 1278
2026
Q1
$64.2K Buy
7,127
+2,335
+49% +$36.8K ﹤0.01% 1277
2025
Q4
$87.4K Buy
4,792
+1,769
+59% +$29.8K ﹤0.01% 1246
2025
Q3
$44.3K Buy
3,023
+1,967
+186% +$33.7K ﹤0.01% 1300
2025
Q2
$19.2K Buy
+1,056
New +$21.5K ﹤0.01% 1342

Other funds holding ADMA

Advisors Asset Management's ADMA Position: Q3 2026 in Review

Advisors Asset Management reduced its ADMA Biologics (ADMA) stake by 18% in Q3 2026, selling an estimated $11.8K and leaving 5,972 shares worth $59.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1314.

Advisors Asset Management first reported a position in ADMA in Q2 2025 and has held it in 6 quarters since. The position peaked at $87.4K in Q4 2025. 330 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

  • Advisors Asset Management held 5,972 shares of ADMA Biologics worth $59.9K as of Q3 2026.
  • Advisors Asset Management sold 1,278 ADMA Biologics shares in Q3 2026, an estimated $11.8K.
  • ADMA Biologics made up ﹤0.01% of Advisors Asset Management's portfolio in Q3 2026, its #1314 holding.
  • Advisors Asset Management first reported a position in ADMA Biologics in Q2 2025 and has held it in 6 quarters since.
  • Advisors Asset Management's ADMA Biologics position peaked at $87.4K in Q4 2025.
  • 330 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on Advisors Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.